Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168802 | 0.96 | P2RY12 (0.60) | P2RY12CYP3A4CYP2C9CYP2D6PKM | |
| SCHEMBL4171965 | 0.91 | P2RY12 (0.69) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL4737200 | 0.89 | P2RY12 (0.61) | P2RY12CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4172769 | 0.88 | P2RY12 (0.41) | P2RY12CYP3A4CYP2C9CYP2D6PKM | |
| SCHEMBL4177858 | 0.87 | P2RY12 (0.55) | P2RY12CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4185978 | 0.87 | P2RY12 (0.56) | P2RY12CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4018215 | 0.86 | P2RY12 (0.75) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL3942745 | 0.85 | P2RY12 (0.41) | P2RY12 | |
| SCHEMBL4185716 | 0.85 | P2RY12 (0.38) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL4170985 | 0.83 | P2RY12 (0.61) | P2RY12CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018166-A1 | New Pyridine Analogues X 161 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | claimed |
| US-20090018166-A1 | New Pyridine Analogues X 161 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018166-A1 | New Pyridine Analogues X 161 | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP3A4 474/4885CYP2C9 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.